Rad51 and BRCA2 - New Molecular Targets for Sensitizing Glioma Cells to Alkylating Anticancer Drugs

doi:10.1371/journal.pone.0027183

PMC full text:

PLoS One. 2011; 6(11): e27183.

Published online 2011 Nov 2. doi: 10.1371/journal.pone.0027183

Copyright/LicenseRequest permission to reuse: Copyright Quiros et al.
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.

<< PrevFigure 2Next >>

Figure 2

An external file that holds a picture, illustration, etc.
Object name is pone.0027183.g002.jpg

Open in a separate window

Knockdown of the HR protein BRCA2 sensitizes glioma cells to O⁶AA chemotherapeutics.

(A) BRCA2 protein expression following knockdown was assessed by western blot. (B) Clonogenic survival following TMZ treatments in transient BRCA2 or non-sense (n.s.) siRNA transfected glioma cells. (C) Clonogenic survival following ACNU treatments in transient BRCA2 or non-sense (n.s.) siRNA transfected glioma cells. (D) Clonogenic survival following ionizing radiation (IR) in transient BRCA2 or non-sense (n.s.) siRNA transfected glioma cells.

Figure 2

Images in this article

Click on the image to see a larger version.